HYUNDAI BIOLAND Co.,Ltd. Stock

Equities

A052260

KR7052260007

Personal Products

End-of-day quote Korea S.E. 06:00:00 2024-05-26 pm EDT 5-day change 1st Jan Change
5,980 KRW -1.64% Intraday chart for HYUNDAI BIOLAND Co.,Ltd. -14.33% +19.84%
Sales 2022 99.15B 72.98M Sales 2023 102B 74.84M Capitalization 150B 110M
Net income 2022 4.76B 3.51M Net income 2023 8.06B 5.93M EV / Sales 2022 2.16 x
Net Debt 2022 12.48B 9.18M Net Debt 2023 9.94B 7.32M EV / Sales 2023 1.57 x
P/E ratio 2022
42.3 x
P/E ratio 2023
18.6 x
Employees 320
Yield 2022
0.52%
Yield 2023
0.7%
Free-Float 15%
More Fundamentals * Assessed data
Dynamic Chart
HYUNDAI BIOLAND Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
HYUNDAI BIOLAND Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hyundai HCN Co.,Ltd. completed the acquisition of 27.94% stake in SKbioland Co., Ltd. from SKC Co., Ltd.. CI
Hyundai HCN Co.,Ltd. agreed to acquire 27.94% stake in SKbioland Co., Ltd. from SKC Co., Ltd. for approximately KRW 120 billion. CI
UCI Co.,Ltd. acquired 30.9% stake in Bio X Co., Ltd. from group of sellers for KRW 20 billion. CI
UCI Co.,Ltd. announced that it has received KRW 20 billion in funding from Pacific Invest Fund, SKbioland Co., Ltd., L&K Investment Co., Ltd. and other investors CI
SKC Co. Ltd. completed the acquisition of an additional 4.39% stake in Bioland Co., Ltd. from Chan Bok Jeong. CI
SKC Co. Ltd. agreed to acquire an additional 4.39% stake in Bioland Co., Ltd. from Chan Bok Jeong for KRW 16.3 billion. CI
Bioland Co., Ltd(KOSDAQ:A052260) added to Russell Global Index CI
SK Holdings Co., Ltd. and Paratus the 1st Special Purpose Company LLC completed the acquisition of 24.31% stake in Bioland Co., Ltd. from Taek-Seon Lee, In-Kyung Im, Young-Kyu Lee, Taek-Wan Lee and Interlees Ltd. CI
SK Holdings Co., Ltd. entered into a contract to acquire additional 24.31% stake in Bioland Co., Ltd. from Taek-Seon Lee, In-Kyung Im, Young-Kyu Lee, Taek-Wan Lee and Interlees Ltd. for KRW 69.3 billion. CI
SKC Eyes Bioland CI
More news
1 day-1.64%
1 week-14.33%
Current month+31.28%
1 month+34.23%
3 months+24.32%
6 months+19.36%
Current year+19.84%
More quotes
1 week
5 900.00
Extreme 5900
7 430.00
1 month
4 485.00
Extreme 4485
7 900.00
Current year
4 215.00
Extreme 4215
7 900.00
1 year
4 215.00
Extreme 4215
7 900.00
3 years
4 215.00
Extreme 4215
12 225.00
5 years
4 215.00
Extreme 4215
24 425.00
10 years
4 215.00
Extreme 4215
24 425.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 20-08-27
Members of the board TitleAgeSince
Chief Executive Officer 56 20-08-27
Director/Board Member 50 -
Director/Board Member 54 20-08-27
More insiders
Date Price Change Volume
24-05-27 5,980 -1.64% 135,295
24-05-24 6,080 -1.46% 182,060
24-05-23 6,170 -1.44% 135,874
24-05-22 6,260 -3.69% 179,569
24-05-21 6,500 -1.66% 899,748

End-of-day quote Korea S.E., May 26, 2024

More quotes
Hyundai Bioland Co Ltd, formerly SK Bio Land Co Ltd, is a Korea-based company mainly engaged in the development and manufacture of raw materials for cosmetics. The Company operates its business through four segments. The Cosmetic Raw Material segment produces products such as portulaca extracts, ulmus extracts, crinum extracts, hyaluronic acids and arbutins. The Pharmaceutical Ingredient segment manufactures and sells products such as phellodendron extracts, ampelopsis extracts and gardenia extracts and others. The Ingredients for Health Functional Food segment produces and distributes red ginseng extract powders, seaweed powders, glucosamine powders, black garlic extract powders, dandelion extract powders, green tea extracts and others. The Medical Device segment involves in the provision of medical equipment such as tissue engineering products, comprised of biological wound dressings and collagen, as well as diagnostic kits, comprised of rapid kits, serological kits and mask packs.
More about the company
  1. Stock Market
  2. Equities
  3. A052260 Stock